Miami Cancer Institute to Present Hematology and Hematological Oncology Research at 2022 ASH Annual Meeting
MIAMI, FL & NEW ORLEANS, LA – December 8, 2022 – Miami Cancer Institute, part of Baptist Health South Florida, today announced its research presentations at this year’s annual meeting of the American Society of Hematology (ASH), December 10-13, at the Ernest N. Morial Convention Center in New Orleans, Louisiana, with a pre-conference scientific workshop program held on December 9. The presentations include novel treatment approaches for relapsed and/or refractory large B-cell lymphomas and thrombotic thrombocytopenic purpura, as well as pre-conference workshops on viral complications following allogeneic stem cell transplants and pregnancy in women with thrombotic microangiopathy.
“I am very pleased about the leading-edge research that my Miami Cancer Institute colleagues will be presenting at this year’s ASH meeting,” said Guenther Koehne, M.D., Ph.D. deputy director of Miami Cancer Institute and chief of blood & marrow transplant and hematologic oncology. “The ASH meeting is a premier opportunity to exchange ideas and share the latest and most promising research in the field that offers real hope for those who urgently need novel treatments for devastating hematologic conditions and malignancies.”
Miami Cancer Institute’s symposium and poster presentations at ASH 2022 include:
Panels, Educational Symposia, and Workshops
Friday, December 9, 2022
Satellite Symposium – State-of-the Art CMV Care: Expert’s Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections
Speaker: Guenther Koehne, M.D., Ph.D.
Time: 11:00 a.m. – 02:00 p.m. CST
Location: La Nouvelle Orleans Ballroom AB
Scientific Workshop – Pregnancy in Women with a History of Thrombotic Microangiopathy
Session host: Camila Masias, M.D.
Time: 04:15 – 04:58 p.m. CST
Location: Rooms 293-294
Sunday, December 11, 2022
Medical Educators Symposium – Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Workforce
Session host: Srikanth Nagalla, MBBS, M.S.
Time: 07:30 – 09:30 a.m. CST
Location: Cypress (Marriott New Orleans Warehouse Arts District)
Monday, December 12, 2022
Most/All Patients with Acquired (Immune) Thrombotic Thrombocytopenic Purpura Receive Caplacizumab
Panelist: Camila Masias, M.D., MPH
Time: 10:30 – 11:45 a.m. CST
Location: Rooms 295-296
Poster Presentations
Sunday, December 11, 2022
Polatuzumab- Rituximab with or without Bendamustine As Second-Line Therapy for Relapsed Refractory Large B-Cell Lymphomas: Single Center Experience
Presenter: Ariel Perez Perez, M.D.
Time: 06:00 – 08:00 p.m. CST
Location: Hall D
Number: 2969
Monday, December 12, 2022
Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell
Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study
Presenter: Yuliya Linhares, M.D.
Time: 06:00 – 08:00 p.m. CST
Location: Hall D
Number: 4910
Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Presenter: Yuliya Linhares, M.D.
Time: 06:00 – 08:00 p.m. CST
Location: Hall D
Number: 4673
For updates from the ASH Annual Meeting, look for #ASH22 on social media and follow Miami Cancer Institute on Twitter at @MiamiCancerInst.
###
About Miami Cancer Institute
Miami Cancer Institute brings to South Florida access to personalized clinical treatments and comprehensive support services delivered with unparalleled compassion. No other cancer program in the region has the combination of cancer-fighting expertise and advanced technology—including the first proton therapy center in South Florida, Latin America and the Caribbean, and one of the only radiation oncology programs in the world with each of the newest radiation therapies in one place—to diagnose and deliver precise cancer treatments that achieve the best outcomes and improve the lives of cancer patients. The Institute offers an impressive roster of established community oncologists and renowned experts, clinical researchers and genomic scientists recruited from the nation’s top cancer centers. Selected as Florida’s only member of the Memorial Sloan Kettering Cancer (MSK) Alliance, Miami Cancer Institute is part of a meaningful clinical collaboration that affords patients in South Florida access to innovative treatments and ensures that the standards of care developed by their multidisciplinary disease management teams match those at MSK.
